BioXcel Therapeutics (BTAI) Price to Book (2018 - 2026)

BioXcel Therapeutics has reported Price to Book for 9 years, with the latest figure at 0.38 in Q2 2026.

• On a quarterly basis, Price to Book fell 243.52% year-over-year to 0.38 in Q2 2026; TTM through Jun 2026 was 0.38, a 243.52% decrease from a year earlier, with the FY2025 full-year figure at 0.2, down 25.66% from the prior year.
• Price to Book was 0.38 for Q2 2026 at BioXcel Therapeutics, down from 0.34 in the prior quarter.
• The five-year high for Price to Book was 33.24 in Q2 2023, with the low at 1.82 in Q3 2023.
• Average Price to Book over 5 years is 2.88, with a median of 0.18 recorded in 2025.
• The sharpest annual moves came in 2023 and 2026: Price to Book soared 1376.32% in 2023, then plunged 243.52% in 2026.
• Over 5 years, Price to Book stood at 7.87 in 2022, then tumbled by 119.84% to 1.56 in 2023, then jumped by 89.58% to 0.16 in 2024, then slipped by 25.66% to 0.2 in 2025, then plunged by 86.84% to 0.38 in 2026.
• The last three Price to Book figures came in at 0.38 (Q2 2026), 0.34 (Q1 2026), and 0.2 (Q4 2025), per Business Quant data.